Gregg Williams Purchases 1,575,231 Shares of Vivani Medical (NASDAQ:VANI) Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams purchased 1,575,231 shares of Vivani Medical stock in a transaction dated Sunday, March 15th. The shares were acquired at an average cost of $1.07 per share, with a total value of $1,685,497.17. Following the transaction, the director directly owned 31,357,183 shares in the company, valued at approximately $33,552,185.81. The trade was a 5.29% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Gregg Williams also recently made the following trade(s):

• On Tuesday, January 27th, Gregg Williams bought 1,351,351 shares of Vivani Medical stock. The stock was bought at an average cost of $1.48 per share, for a total transaction of $1,999,999.48.
• On Thursday, January 15th, Gregg Williams acquired 1,737,765 shares of Vivani Medical stock. The shares were bought at an average price of $1.14 per share, with a total value of $1,981,052.10.

Vivani Medical Trading Down 0.8%

Vivani Medical stock opened at $1.21 on Wednesday. The firm has a 50 day moving average of $1.28 and a 200 day moving average of $1.36. The firm has a market capitalization of $94.59 million, a price-to-earnings ratio of -2.69 and a beta of 3.17. Vivani Medical, Inc. has a 12-month low of $0.91 and a 12-month high of $1.92.

Wall Street Analyst Weigh In

Several analysts have recently commented on VANI shares. Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, January 9th. Wall Street Zen raised shares of Vivani Medical to a “sell” rating in a report on Saturday, November 22nd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $4.00.

Institutional Trading of Vivani Medical

Hedge funds have recently bought and sold shares of the business. Panagora Asset Management Inc. acquired a new position in shares of Vivani Medical during the 2nd quarter worth approximately $25,000. Citadel Advisors LLC acquired a new stake in shares of Vivani Medical in the third quarter valued at approximately $26,000. Susquehanna International Group LLP increased its holdings in shares of Vivani Medical by 100.5% in the third quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after purchasing an additional 16,200 shares during the last quarter. Geode Capital Management LLC lifted its position in Vivani Medical by 29.6% during the fourth quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock worth $568,000 after buying an additional 105,398 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Vivani Medical by 118.4% during the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after buying an additional 53,127 shares in the last quarter. Institutional investors and hedge funds own 6.78% of the company’s stock.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.